Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.

Abstract

BACKGROUND The current study was conducted to evaluate the efficacy of sorafenib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, when added to standard radiotherapy and temozolomide in the first-line treatment of patients with glioblastoma multiforme. METHODS After initial surgical resection or biopsy, patients with newly… (More)
DOI: 10.1002/cncr.25275

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.